8-K: Milestone Pharma: CARDAMYST Coverage Soars, AFib Trial Begins

Milestone Pharmaceuticals announced Q2 2026 results, highlighting a significant increase in insurance coverage for CARDAMYST to over 50% of commercially insured lives and the activation of its Phase 3 trial for atrial fibrillation.

Summary

• Milestone Pharmaceuticals reported Q2 2026 financial results and provided corporate updates.
• CARDAMYST (etripamil) nasal spray now has coverage for over 50% of U.S. commercially insured lives, a substantial increase from approximately 25% in Q2.
• The Phase 3 registrational trial (ReVeRA-301) for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR) has activated its first clinical sites.
• The company ended Q2 2026 with $170.6 million in cash, cash equivalents, and short-term investments, providing a runway into the second half of 2027.
• Product revenue for Q2 2026 was $0.6 million, with $0.8 million for the six months ended June 30, 2026.
• Net loss for Q2 2026 was $28.6 million ($0.21 per share), compared to a net loss of $13.0 million ($0.20 per share) in the prior year period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by significant progress in insurance coverage for CARDAMYST and the activation of a key Phase 3 trial, despite continued net losses.

Positives

• Significant increase in CARDAMYST insurance coverage to over 50% of U.S. commercially insured lives, up from approximately 25% in Q2.
• Activation of the first clinical sites for the Phase 3 ReVeRA-301 trial for etripamil in AFib-RVR, advancing a potential second cardiovascular indication.
• Strong cash position of $170.6 million as of June 30, 2026, sufficient to cover operating expenses into H2 2027.
• Growth in CARDAMYST prescribers, with over 800 unique prescribers by June 30, 2026, up from approximately 200 at the end of Q1.
• Increased filled prescriptions for CARDAMYST to over 1,500 by June 30, 2026, up from approximately 300 at the end of Q1.
• Nomination of CARDAMYST for the 2026 Prix Galien USA Awards for Best Pharmaceutical Product.
• European Medicines Agency (EMA) review for etripumil in PSVT remains on track for a decision in H1 2027.
• Publication of two new articles in the Journal of the American College of Cardiology: Advances supporting CARDAMYST's efficacy and safety.

Negatives

• Net loss for Q2 2026 increased to $28.6 million from $13.0 million in the prior year period.
• Selling, general and administrative expenses significantly increased to $22.6 million in Q2 2026 from $8.9 million in the prior year period, primarily due to CARDAMYST launch costs.
• Product revenue remains low at $0.6 million for Q2 2026.

Risks

• Potential for delays in the EMA decision for etripamil in Europe, expected in H1 2027.
• Uncertainties related to the review of the New Drug Application for etripamil in China by the NMPA.
• Risks associated with the complexity of cleaning, verifying, and analyzing clinical trial data.
• Uncertainty regarding whether clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications.
• General economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs and conflicts.
• Risks related to pandemics and public health emergencies.
• Risks related to the sufficiency of capital resources and the ability to raise additional capital in the current economic climate.

Future Outlook

The company expects its cash, cash equivalents, and short-term investments to be sufficient to cover operating expenses and capital expenditures into the second half of 2027. The Phase 3 ReVeRA-301 trial for AFib-RVR is on track to enroll the first patient in the second half of 2026. A decision from the European Medicines Agency (EMA) regarding the marketing authorization application for etripamil for PSVT in Europe is expected in the first half of 2027.

Management Comments

• "We continue to make steady progress on the launch of CARDAMYST for PSVT supported by prescription growth from a widening base of new prescribers and a meaningful recent increase in insurance coverage."
• "We are confident that this increased coverage paired with optimized sales and marketing strategies positions us to drive acceleration of CARDAMYST prescriptions moving forward."
• "Separately, we have activated several sites in our Phase 3 ReVeRA-301 trial in AFib-RVR and look forward to enrolling the first patient."
• "AFib-RVR is one of the most common heart arrhythmias, affecting millions of Americans. The trial is evaluating the same self-administered regimen already approved in PSVT, giving us a clear path toward extending etripamil to a larger, adjacent patient population."

Industry Context

StockSavvy.ai notes that the significant increase in insurance coverage for CARDAMYST is a critical development in the competitive landscape of cardiovascular treatments, potentially accelerating market penetration. The advancement of the AFib-RVR trial positions Milestone to compete in a larger indication, mirroring strategies seen in other biopharmaceutical companies seeking to expand the utility of their approved drugs.

Comparison to Industry Standards

• The increase in insurance coverage to over 50% for a newly launched drug like CARDAMYST is a strong positive indicator, often a key hurdle for market adoption in the U.S. pharmaceutical sector.
• The progression to Phase 3 trials for a second indication (AFib-RVR) is a standard and crucial step for biopharmaceutical companies aiming to maximize the value of a drug candidate, similar to strategies employed by companies like Bristol Myers Squibb or Pfizer with their cardiovascular portfolios.
• The cash runway extending into H2 2027 is generally considered adequate for a commercial-stage biopharmaceutical company, allowing for continued development and operational expenses without immediate capital constraints, though it is shorter than some larger, more established companies.

Stakeholder Impact

• Shareholders: Positively impacted by increased insurance coverage for CARDAMYST and progress in clinical trials, potentially leading to future revenue growth. Negatively impacted by the increased net loss and higher operating expenses.
• Patients with PSVT: Benefit from increased accessibility to CARDAMYST due to wider insurance coverage and growing prescriber base.
• Patients with AFib-RVR: Potential future beneficiaries if etripamil proves effective and is approved for this indication.
• Employees: Increased SG&A expenses suggest investment in personnel and operations related to the CARDAMYST launch and clinical development.
• Insurers: Increased coverage for CARDAMYST reflects a growing acceptance of the drug's utility.

Next Steps

• Enroll the first patient in the ReVeRA-301 Phase 3 trial for AFib-RVR in the second half of 2026.
• Await a decision from the European Medicines Agency (EMA) on the marketing authorization application for etripamil for PSVT in the first half of 2027.
• Continue engagement with China's National Medical Products Administration (NMPA) for the New Drug Application of etripamil for PSVT, managed by partner Everest Medicines.
• Present findings on 'The Impact of Paroxysmal Supraventricular Tachycardia on Patients Daily Life and Quality of Life Between Episodes' at the upcoming European Society of Cardiology (ESC) Congress (August 28-31, 2026).

Key Dates

Recommendation

The significant increase in CARDAMYST insurance coverage and the advancement of the AFib-RVR trial are strong positives. However, the continued net losses, increasing SG&A expenses, and low product revenue warrant a cautious approach. The company's cash runway provides some comfort, but further revenue growth and profitability are needed to justify a more bullish stance. A 'hold' reflects the balance of positive developments against ongoing financial challenges.

Keywords

CARDAMYST, etripamil, PSVT, AFib-RVR, cardiovascular, biopharmaceutical, Phase 3 trial, financial results